QSA Global, Inc. (QSA) and Niowave, Inc. (Niowave) have joined forces in an exciting partnership to advance the field of radiopharmaceutical technology. This collaboration aims to transfer Niowave’s innovative radium-226 (Ra-226) processing technology to QSA and co-develop a scalable radium purification process.
Niowave has been a leader in processing Ra-226 and producing actinium-225 (Ac-225) since 2017. Under this partnership, QSA now has a license to utilize Niowave’s cutting-edge technology for Ra-226 processing, and the two companies will work together to develop a scalable purification process. The purified Ra-226 will be provided to Niowave to enhance their Ac-225 production, which is critical for cancer treatments.
Through this collaboration, QSA and Niowave aim to increase the availability of high-purity Ra-226 for the radioisotope ecosystem. The partnership will also help meet the growing demand for Ac-225 and support the healthcare industry in advancing patient treatments.
Jake BournVP/GM at QSA expressed excitement about the partnership and highlighted how it will expand capabilities for Ra-226 processing and meet the increasing demand for Ac-225. Niowave’s CEO, Mike Zamiara, emphasized the significance of the partnership in maximizing Ac-225 capacity and providing a stable supply to support medical applications.
Both companies are committed to driving innovation and improving the radiopharmaceutical supply chain to benefit patients and advance nuclear medicine. QSA Global, Inc. is well-known for providing high-quality radioisotope products and services with a focus on safety, reliability, and innovation. Niowave, Inc. is a pioneer in medical isotope production, utilizing advanced accelerator technology for cancer treatment and other medical applications.
For more information about this partnership and the innovative solutions being developed, please contact Niowave, Inc. or QSA Global, Inc. at the provided phone numbers. This collaboration marks a significant advancement in radiopharmaceutical technology and demonstrates a commitment to enhancing patient outcomes and advancing healthcare.
Source link
